Literature DB >> 22352837

Metabolic adaptation to a disruption in oxygen supply during myocardial ischemia and reperfusion is underpinned by temporal and quantitative changes in the cardiac proteome.

Xin Li1, Fatih Arslan, Yan Ren, Sunil S Adav, Kian Keong Poh, Vitaly Sorokin, Chuen Neng Lee, Dominique de Kleijn, Sai Kiang Lim, Siu Kwan Sze.   

Abstract

Despite decades of intensive research, there is still no effective treatment for ischemia/reperfusion (I/R) injury, an important corollary in the treatment of ischemic disease. I/R injury is initiated when the altered biochemistry of cells after ischemia is no longer compatible with oxygenated microenvironment (or reperfusion). To better understand the molecular basis of this alteration and subsequent incompatibility, we assessed the temporal and quantitative alterations in the cardiac proteome of a mouse cardiac I/R model by an iTRAQ approach at 30 min of ischemia, and at 60 or 120 min reperfusion after the ischemia using sham-operated mouse heart as the baseline control. Of the 509 quantified proteins identified, 121 proteins exhibited significant changes (p-value<0.05) over time and were mostly clustered in eight functional groups: Fatty acid oxidation, Glycolysis, TCA cycle, ETC (electron transport chain), Redox Homeostasis, Glutathione S-transferase, Apoptosis related, and Heat Shock proteins. The first four groups are intimately involved in ATP production and the last four groups are known to be important in cellular antioxidant activity. During ischemia and reperfusion, the short supply of oxygen precipitates a pivotal metabolic switch from aerobic metabolism involving fatty acid oxidation, TCA, and phosphorylation to anaerobic metabolism for ATP production and this, in turn, increases reactive oxygen species (ROS) formation. Therefore the implication of these 8 functional groups suggested that ischemia-reperfusion injury is underpinned in part by proteomic alterations. Reversion of these alterations to preischemia levels took at least 60 min, suggesting a refractory period in which the ischemic cells cannot adjust to the presence of oxygen. Therefore, therapeutics that could compensate for these proteomic alterations during this interim refractory period could alleviate ischemia-reperfusion injury to enhance cellular recovery from an ischemic to a normoxic microenvironment. Among the perturbed proteins, Park7 and Ppia were selected for further investigation of their functions under hypoxia. The results show that Park7 plays a key role in regulating antioxidative stress and cell survival, and Ppia may function in coping with the unfolded protein stress in the I/R condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352837     DOI: 10.1021/pr201025m

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  19 in total

1.  Tolerance to ischaemic injury in remodelled mouse hearts: less ischaemic glycogenolysis and preserved metabolic efficiency.

Authors:  Waleed G T Masoud; Osama Abo Al-Rob; Yang Yang; Gary D Lopaschuk; Alexander S Clanachan
Journal:  Cardiovasc Res       Date:  2015-07-06       Impact factor: 10.787

Review 2.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

3.  Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology.

Authors:  Warren D Gray; Kristin M French; Shohini Ghosh-Choudhary; Joshua T Maxwell; Milton E Brown; Manu O Platt; Charles D Searles; Michael E Davis
Journal:  Circ Res       Date:  2014-10-24       Impact factor: 17.367

Review 4.  Extracellular vesicles and cardiovascular disease therapy.

Authors:  Jérémy Amosse; Maria Carmen Martinez; Soazig Le Lay
Journal:  Stem Cell Investig       Date:  2017-12-30

Review 5.  A New Era of Cardiac Cell Therapy: Opportunities and Challenges.

Authors:  Ke Huang; Shiqi Hu; Ke Cheng
Journal:  Adv Healthc Mater       Date:  2018-12-13       Impact factor: 9.933

Review 6.  Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors:  Sunil S Adav; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-11-03       Impact factor: 4.041

Review 7.  New therapeutic approaches of mesenchymal stem cells-derived exosomes.

Authors:  Jana Janockova; Lucia Slovinska; Denisa Harvanova; Timea Spakova; Jan Rosocha
Journal:  J Biomed Sci       Date:  2021-05-25       Impact factor: 8.410

8.  Adipose stem cell secretome markedly improves rodent heart and human induced pluripotent stem cell-derived cardiomyocyte recovery from cardioplegic transport solution exposure.

Authors:  Bradley W Ellis; Dmitry O Traktuev; Stephanie Merfeld-Clauss; Uryan Isik Can; Meijing Wang; Ray Bergeron; Pinar Zorlutuna; Keith L March
Journal:  Stem Cells       Date:  2020-12-23       Impact factor: 6.277

9.  A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis.

Authors:  Lisa M Wolfe; Usha Veeraraghavan; Susan Idicula-Thomas; Stephan Schürer; Krister Wennerberg; Robert Reynolds; Gurdyal S Besra; Karen M Dobos
Journal:  Mol Cell Proteomics       Date:  2013-03-05       Impact factor: 5.911

10.  Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure.

Authors:  Aishwarya Prakash; Gustavo E Crespo-Avilan; Sauri Hernandez-Resendiz; Sang-Ging Ong; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.